Barclays analyst Brandon Oglenski lowered the firm’s price target on RXO Inc. (RXO) to $24 from $30 and keeps an Overweight rating on the shares. Another year and another wait-and-see outlook for RXO, the firm says. Barclays notes that deterioration in core brokerage earnings following last year’s Coyote acquisition suggests a 20% lower 2025 earnings outlook, which likely explains the materially negative reaction in the company’s shares today.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio